IRF1 and breast carcinoma: The anticancer effects of Dp-3-G were due to suppression of Akt stimulation and enhanced IRF1 expression which are involved in controlling HOTAIR expression in carcinogen treated MCF10A, other breast cancer cells and in xenografted breast tumor.